Search
ACADIA Pharmaceuticals Inc
ACADAdd to Watchlist
21.620USD
+0.020+0.09%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
3.70BMarket Cap
9.70P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of ACADIA Pharmaceuticals Inc is 7.90, ranking 270 out of 389 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 35.00 and a low of 17.00.
Analyst Rating
Based on
21
analysts
Buy
Current Rating
31.556
Target Price
+45.96%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
ACADIA Pharmaceuticals Inc
ACAD
21
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is ACADIA Pharmaceuticals Inc's expected revenue for the next quarter?
ACADIA Pharmaceuticals Inc's expected revenue is 296.64M.
What is ACADIA Pharmaceuticals Inc's price target?
Analysts forecast that ACADIA Pharmaceuticals Inc's price target is USD 30.00, with the highest forecast at USD 35.00 and the lowest forecast at USD 17.00.
How have ACADIA Pharmaceuticals IncACAD's recent earnings per share performed?
The market expectation was USD 0.02, while ACADIA Pharmaceuticals IncACAD's earnings per share (EPS) for the previous quarter was USD 1.61. EPS for the next quarter is expected at USD 0.06.
What is the analyst rating for ACADIA Pharmaceuticals Inc?
Based on the ratings of ACADIA Pharmaceuticals Inc's stock from 21 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
